Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 4/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.36 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
| ▸ | TYR | P14679 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16645380 | 0.81 | MME (0.36) | GRIA4GRIA1GRIA2GRIA3KEAP1 | |
| SCHEMBL20831024 | 0.74 | TAAR1 (0.35) | — | |
| SCHEMBL3206859 | 0.73 | CPB2 (0.46) | IRAK4HTTKDM4E | |
| SCHEMBL10684223 | 0.70 | CPB2 (0.35) | GRIA4GRIA1GRIA2GRIA3BRD4 | |
| SCHEMBL22367502 | 0.69 | BRD4 (0.34) | GRIA4GRIA1GRIA2GRIA3BRD4 | |
| SCHEMBL28427202 | 0.67 | KMT2A (0.31) | — | |
| SCHEMBL10059980 | 0.67 | GRIA4 (0.54) | GRIA4GRIA1GRIA2GRIA3SLC1A3 | |
| SCHEMBL19389423 | 0.67 | GRIA4 (0.54) | GRIA4GRIA1GRIA2GRIA3SLC1A3 | |
| SCHEMBL20204351 | 0.66 | — | — | |
| SCHEMBL9914065 | 0.66 | BRD4 (0.39) | BRD4NR1H4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776977-B2 | PSMA-targeting compounds and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-10-03 | — | — | US | disclosed |
| US-20150104387-A1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150104387-A1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | FOLH1, KLK3, PSMA2 | GRIA4 2971/4885GRIA1 2604/4885GRIA2 2794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.